HEALTH● LOWAug 13 · Aug 13, 2026, 11:18 PM
Belite Bio outlines February 12, 2027 PDUFA date for Tinlarebant in Stargardt disease following FDA priority review acceptance
Seeking Alpha Tech
Belite Bio has received FDA priority review acceptance for Tinlarebant in Stargardt disease, with a PDUFA date set for February 12, 2027. This marks a key milestone in the drug's development and potential availability for patients.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH42m agoUganda says it has no active Ebola cases, but infections in Kenya and Nigeria are prompting fresh scrutinyDW News [en]HEALTH51m agoAfrica CDC probes possible link between Ebola cases in Nigeria, KenyaPremium TimesHEALTH51m agoRobert Waldinger, Harvard psychiatrist expert in longevity and well-being: "People in their 80s reflected on their lives, they were asked what they were most proud of, it was never an award won or money accumulated, but their connections with other people"ClarínHEALTH1h agoEbola: Nigerian govt urges 15 states to speed up preparednessPremium Times